Company intelligence / Profile preview

Circularity

Pasadena, California, United Statescircularity-gap.world ↗

Ownership: Private
Development stage: Other

Overview

D'OXYVA has been clinically validated to significantly improve microcirculation and nerve function with a decade-long record of zero adverse event reports. The company’s pivotal multi-site clinical trial for diabetic foot ulcer treatment and amputation prevention was ongoing as of late 2022, with evidence collection supported by leading US universities. The product has been sold in over two dozen countries.

Therapeutic areas: RheumatologyEndocrinologyCardiovascularNeurology
Modalities: DeviceNoninvasive drug delivery technology (specifically CO₂-based transdermal delivery)Small molecule (as delivered by device; not primary focus)
Industry: Therapeutic Medical Devices

Partnerships

Universities including UCLA, MIT, Yale, Harvard, Drexel and others collaborating on pivotal trials/evidence collection.

Beyond the preview

Go deeper on Circularity.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Circularity.

Explore the full profile